Denmark · Delayed Price · Currency is DKK Coloplast Earnings Call Transcripts
Fiscal Year 2026
-
Guidance for FY 2025/2026 was revised down due to Kerecis market challenges and currency headwinds, with organic growth now expected at 5%-6%. Chronic Care and Interventional Urology remain strong, while European wound dressings face pricing pressures.
-
Q1 saw 6% organic revenue growth and 3% EBIT growth in constant currencies, with strong Interventional Urology performance offsetting Kerecis' Medicare-related headwinds. Full-year guidance is maintained, with Kerecis' margin expected to recover and net profit to rise significantly year-over-year.
Fiscal Year 2025
-
The AGM reviewed solid financials with 7% organic growth, approved a DKK 23 per share dividend, and launched the Impact4 strategy targeting 7%-8% growth through 2030. Leadership transitions and a new board member were confirmed, with all proposals adopted.
-
Organic growth reached 7% with a 28% EBIT margin before special items, driven by strong chronic care but offset by product recalls and market volatility in other segments. Guidance for 2025-2026 targets 7% organic growth and improved profitability, with continued investment in innovation and efficiency.
-
A new five-year strategy targets 7%-8% organic growth, over 20% ROIC, and enhanced customer-centricity, with major investments in technology, efficiency, and sustainability. Chronic Care and Wound & Tissue Repair are key growth drivers, while China and pricing remain challenges.
-
Organic revenue grew 7% with stable EBIT margin, driven by strong chronic care and Kerecis growth, despite headwinds from product returns in China and FX. New strategy and reorganization aim to boost innovation and value creation, with full-year guidance reaffirmed.
-
Organic growth and EBIT margin guidance were lowered due to a product recall and China slowdown, with management changes aimed at improving execution. Strong performance from Kerecis and Atos, new product launches, and margin initiatives support a positive long-term outlook.
-
Q1 delivered 8% organic growth and a 27% EBIT margin before special items, with strong performance in Chronic Care, Advanced Wound Care, and Voice and Respiratory Care. Guidance for FY 2024/25 remains at 8%-9% organic growth and 28% EBIT margin, despite product recall and regulatory delays.
Fiscal Year 2024
-
The AGM reviewed strong 8% organic growth, a 27% EBIT margin, and a DKK 22 per share dividend. Strategic focus remains on four growth platforms, sustainability, and expanding production, while addressing margin pressures and shareholder questions.
-
Delivered 8% organic growth and 27% EBIT margin before special items for FY 2023-24, with strong contributions from new product launches and acquisitions. Guidance for FY 2024-25 is 8%-9% organic growth and 28% EBIT margin, with Kerecis and innovation as key drivers.
-
Delivered 8% organic growth and a 27% EBIT margin before special items, with strong performance in advanced wound care and new product launches. Kerecis integration is on track, but short-term U.S. distribution disruptions and currency headwinds impacted results. Guidance for 8% organic growth and 27-28% EBIT margin is maintained.
-
Strong organic growth, margin recovery, and robust innovation pipeline underpin a positive outlook, with four growth platforms and successful M&A integration driving future performance. Kerecis accelerates U.S. biologics leadership, supported by clinical evidence and high margins.